Jon Kayyem - GenMark Diagnostics Insider

GNMK -- USA Stock  

USD 6.98  0.08  1.13%

Founder and Sr. VP of RandD
Dr. Jon Faiz Kayyem, Ph.D., is serving as Senior Vice President Research and Development of GenMark Diagnostics Inc. Jon Faiz Kayyem, Ph.D. has served as Senior Vice President, Research and Development since June 2013. Dr. Kayyem previously served as the Companys Chief Scientific Officer from August 2010 to June 2013. Dr. Kayyem served as President and Chief Executive Officer of the Company from May 2010 to August 2010. From August 2009 to May 2010, Dr. Kayyem served as President and Chief Executive Officer of Osmetech plc and Chairman of the board of directors of Osmetech plc from January 2009 to August 2009. Dr. Kayyem attended Yale University and received a combined M.S. and B.S. in Molecular Biophysics and Biochemistry in 1985. Dr. Kayyem received his Ph.D. in Molecular Biology in 1991 from The California Institute of Technology
Age: 52  Founder Since 2013  Ph.D    
760-448-4300  http://www.genmarkdx.com
Kayyem remained at Caltech as a Senior Research Fellow until 1995, when he founded Clinical Micro Sensors to commercialize technical innovations he developed while at Caltech. In 2000, Clinical Micro Sensors was sold to Motorola, Inc., and subsequently purchased by Osmetech plc in 2005. In 2004, Dr. Kayyem left Clinical Micro Sensors and cofounded the biotechnology fund management company, Efficacy Capital Limited, where he served as managing partner until September 2009.

Jon Kayyem Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (40.49) % which means that it has lost $40.49 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (132.48) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 28.3 M in liabilities with Debt to Equity (D/E) ratio of 45.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. GenMark Diagnostics has Current Ratio of 2.73 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California. GenMark Diagnostics operates under Medical Devices classification in USA and traded on BATS Exchange. It employs 517 people.GenMark Diagnostics (GNMK) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 517 people. GenMark Diagnostics is listed under Medical Equipment category by Fama And French industry classification.

GenMark Diagnostics Leadership Team

James McNally, President, MBA
Michael Gleeson, SVP
Kevin OBoyle, Director
Jennifer Williams, SVP
Scott Mendel, CFO, MBA
Ingo Chakravarty, SVP
James Fox, Director
Jon Kayyem, Founder, Ph.D
Eric Stier, President
Michael Kagnoff, Director
Hany Massarany, CEO, MBA
Lisa Giles, Director
Daryl Faulkner, Director

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Arbitrage Now
   

Cryptocurrency Arbitrage

Find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage
All  Next Launch Cryptocurrency Arbitrage

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.